C. Libenciuc

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Matthieu Texier, Emilie Lanoy, Caroline Robert, 2016, Nature Reviews Clinical Oncology.

Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation.

F. André, S. Shen, C. Robert, 2020, Cell reports.

A dose escalation phase 1 study of radiotherapy (RT) in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab (Ipi) in patients (pts) with metastatic melanoma

A. Eggermont, N. Chaput, J. Adam, 2016 .

Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma

N. Sonenberg, A. Eggermont, J. Adam, 2018, Nature Medicine.

Dermatological Complications of Systemic Therapies for Melanoma

R. Dummer, M. Lacouture, C. Robert, 2020, Cutaneous Melanoma.

Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma.

C. Robert, O. Lambotte, C. Mateus, 2019, European journal of cancer.

Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation.

F. André, C. Robert, J. Scoazec, 2020, Cell reports.

Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma

N. Sonenberg, A. Eggermont, J. Adam, 2018, Nature Medicine.